Health care stocks advanced Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.4%.
The iShares Biotechnology ETF (IBB) rose 1.8%.
In corporate news, Pfizer (PFE) secured exclusive global rights, excluding China, to biopharmaceutical firm 3SBio's cancer treatment candidate in a licensing deal worth up to $6.05 billion. Pfizer shares gained 2.1%.
The US Food and Drug Administration plans to require new clinical trials prior to approval of COVID-19 boosters for healthy Americans under the age of 65, agency leaders said Tuesday in a post published on the New England Journal of Medicine. Moderna (MRNA) shares were rising past 8%.
NeurAxis' (NRXS) shares jumped more than 64% after the company said the US Food and Drug Administration granted clearance to expand the use of its IB-Stim device to treat functional abdominal pain linked to functional dyspepsia and nausea in patients aged 8 to 21.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。